Cargando…
Anti‐C1q autoantibodies may not serve as an adequate biomarker for lung manifestations in systemic sclerosis: a single‐centre, cross‐sectional study
Autores principales: | Dijkstra, D.J., Liem, S.I.E., van Leeuwen, N.M., Fehres, C.M., de Vries‐Bouwstra, J.K., Trouw, L.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453845/ https://www.ncbi.nlm.nih.gov/pubmed/33913512 http://dx.doi.org/10.1111/bjd.20412 |
Ejemplares similares
-
Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences
por: Mahler, Michael, et al.
Publicado: (2013) -
Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis
por: Wortel, Corrie M, et al.
Publicado: (2023) -
Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature
por: van Leeuwen, Nina M., et al.
Publicado: (2021) -
Circulating Levels of Anti-C1q and Anti-Factor H Autoantibodies and Their Targets in Normal Pregnancy and Preeclampsia
por: Dijkstra, Douwe Jan, et al.
Publicado: (2022) -
Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations
por: Monahan, Rory C, et al.
Publicado: (2022)